FGF-23 has both short-term beneficial (reduction in serum phosphate level) and long-term adverse effects, as its circulating concentration progressively increases while GFR falls down, achieving levels that are several hundred times the normal range in late CKD stages [12]. Here, FGF23 is linked to chronic kidney disease.